Are Probiotics or Prebiotics Useful in Pediatric Irritable Bowel Syndrome or Inflammatory Bowel Disease?
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Treatment options for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) are notoriously either inadequate (IBS) or loaded with potentially serious side effects and risks (IBD). In recent years, a growing interest in effective and safer alternatives has focused on the potential role of probiotics and their metabolic substrates, prebiotics. It is in fact conceivable that the microbiome might be targeted by providing the metabolic fuel needed for the growth and expansion of beneficial microorganisms (prebiotics) or by administering to the host such microorganisms (probiotics). This review presents a concise update on currently available data, with a special emphasis on children. Data for prebiotics in IBS are scarce. Low doses have shown a beneficial effect, while high doses are counterproductive. On the contrary, several controlled trials of probiotics have yielded encouraging results. A meta-analysis including nine randomized clinical trials in children showed an improvement in abdominal pain for Lactobacillus GG, Lactobacillus reuteri DSM 17938, and the probiotic mixture VSL#3. The patients most benefiting from probiotics were those with predominant diarrhea or with a post-infectious IBS. In IBD, the use of prebiotics has been tested only rarely and in small scale clinical trials, with mixed results. As for probiotics, data in humans from about three dozens clinical trials offer mixed outcomes. So far, none of the tested probiotics has proven successful in Crohn's disease, while in ulcerative colitis a recent meta-analysis on 12 clinical trials (1 of them in children) showed efficacy for the probiotic mixture VSL#3 in contributing to induce and to maintain remission. It is evident that this is a rapidly evolving and promising field; more data are very likely to yield a better understanding on what strains should be used in different specific clinical settings and in what doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The interplay between the intestinal microbiota and the brain
Collins, S. M., Surette, M., & Bercik, P. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2876 · Cited by 1,611 · cited 1×
“How could probiotics be useful in IBS? IBS appears often to follow an episode of gastroenteritis (“post-infectious IBS”), (20) and intestinal microbiota changes have been described in patients with IBS (21–23); furthermore, it is quite conceivable that microbiota may interfere with additional factors involved in the p…”
BackgroundKassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939
Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome
Saulnier, D. M., Riehle, K., Mistretta, T., Diaz, M., Mandal, D., Raza, S., Weidler, E. M., Qin, X., Coarfa, C., Milosavljevic, A., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.072 · Cited by 672
Ong, D. K., Mitchell, S. B., Barrett, J. S., Shepherd, S. J., Irving, P. M., Biesiekierski, J. R., Smith, S., Gibson, P. R., & Muir, J. G. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06370.x · Cited by 583 · cited 1×
“fact, it has been shown that a diet high in fermentable carbohydrates elevated hydrogen gas in 15 patients with IBS and 15 health control patients (62).”
BackgroundSILK, D. B. A., DAVIS, A., VULEVIC, J., TZORTZIS, G., & GIBSON, G. R. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03911.x · Cited by 551
Abdominal pain and irritable bowel syndrome in adolescents: a community-based study
Hyams, J. S., Burke, G., Davis, P. M., Rzepski, B., & Andrulonis, P. A. (1996) · The Journal of Pediatrics · doi:10.1016/s0022-3476(96)70246-9 · Cited by 532
Sood, A., Midha, V., Makharia, G. K., Ahuja, V., Singal, D., Goswami, P., & Tandon, R. K. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.016 · Cited by 513
Tursi, A., Brandimarte, G., Papa, A., Giglio, A., Elisei, W., Giorgetti, G. M., Forti, G., Morini, S., Hassan, C., Pistoia, M. A., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.218 · Cited by 489
Lindsay, J. O. (2006) · Gut · doi:10.1136/gut.2005.074971 · Cited by 471 · cited 1×
“An open-label study with FOS supplementation in 10 adult CD patients (69) showed that FOS improved disease activity index, increased fecal bifidobacteria concentrations and modified mucosal dendritic cell function.”
BackgroundCarroll, I. M., Ringel‐Kulka, T., Siddle, J. P., & Ringel, Y. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01891.x · Cited by 425
World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics October 2011
Guarner, F., Khan, A. G., Garisch, J., Eliakim, R., Gangl, A., Thomson, A., Krabshuis, J., Lemair, T., Kaufmann, P., de Paula, J. A., et al. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182549092 · Cited by 418
Shen, J., Zuo, Z.-X., & Mao, A.-P. (2014) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000437495.30052.be · Cited by 364
Benjamin, J. L., Hedin, C. R. H., Koutsoumpas, A., Ng, S. C., McCarthy, N. E., Hart, A. L., Kamm, M. A., Sanderson, J. D., Knight, S. C., Forbes, A., et al. (2011) · Gut · doi:10.1136/gut.2010.232025 · Cited by 361 · cited 1×
“A more recent RCT in 103 patients with CD randomized to receive FOS (n = 54) or placebo (n = 49) failed to show any significant difference in the number of patients achieving a clinical response between the FOS and placebo groups (70).”
BackgroundMeta-analysis of probiotics for the treatment of irritable bowel syndrome
McFarland, L. V., & Dublin, S. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.2650 · Cited by 341
Guandalini, S., Magazzù, G., Chiaro, A., La Balestra, V., Di Nardo, G., Gopalan, S., Sibal, A., Romano, C., Canani, R. B., Lionetti, P., et al. (2010) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e3181ca4d95 · Cited by 273
Self-citationGAWROŃSKA, A., DZIECHCIARZ, P., HORVATH, A., & SZAJEWSKA, H. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03175.x · Cited by 251
Jonkers, D., Penders, J., Masclee, A., & Pierik, M. (2012) · Drugs · doi:10.2165/11632710-000000000-00000 · Cited by 240
The microbiota-gut-brain axis in functional gastrointestinal disorders
De Palma, G., Collins, S. M., & Bercik, P. (2014) · Gut Microbes · doi:10.4161/gmic.29417 · Cited by 157 · cited 1×
“In IBS, alterations in the gut microbiota composition have been well described (reviewed in a recent report by the Rome working team) (11) and recent evidence has elucidated the growing importance of the microbiota–gut–brain axis in the development of IBS (12).”
BackgroundQuigley, E. M. M., & Flourie, B. (2007) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2006.00879.x · Cited by 151 · cited 1×
“Changes in gastrointestinal motility, brain/gut interaction, lowgrade inflammation, psychosocial disturbance, visceral hypersensitivity, and altered microbiota appear to contribute to various extents to its onset (17, 18).”
BackgroundBanaszkiewicz, A., & Szajewska, H. (2005) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.10.022 · Cited by 150
Lactobacillus casei rhamnosus Lcr35 in children with chronic constipation
BU, L., CHANG, M., NI, Y., CHEN, H., & CHENG, C. (2007) · Pediatrics International · doi:10.1111/j.1442-200x.2007.02397.x · Cited by 145
Paineau, D., Payen, F., Panserieu, S., Coulombier, G., Sobaszek, A., Lartigau, I., Brabet, M., Galmiche, J.-P., Tripodi, D., Sacher-Huvelin, S., et al. (2008) · British Journal of Nutrition · doi:10.1017/s000711450779894x · Cited by 142 · cited 1×
“The third study involved 105 patients with functional bowel disorders who were administered 5 g/day of oligofructose (60).”
BackgroundKorterink, J. J., Ockeloen, L., Benninga, M. A., Tabbers, M. M., Hilbink, M., & Deckers‐Kocken, J. M. (2014) · Acta Paediatrica · doi:10.1111/apa.12513 · Cited by 115
Guerra, P. V. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i34.3916 · Cited by 106
Lactobacillus reuteri in children with functional abdominal pain (FAP)
Romano, C., Ferrau', V., Cavataio, F., Iacono, G., Spina, M., Lionetti, E., Comisi, F., Famiani, A., & Comito, D. (2014) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2010.01797.x · Cited by 99 · cited 1×
“reuteri DSM 17938’s significant decrease of abdominal pain intensity persisted after the removal of the probiotic, indicating a lasting effect of the supplementation (31).”
BackgroundEffects of Bifidobacterium infantis 35624 on Post-Inflammatory Visceral Hypersensitivity in the Rat
Johnson, A. C., Greenwood-Van Meerveld, B., & McRorie, J. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1730-y · Cited by 76
Cited by
Diet and nutritional factors in inflammatory bowel diseases
Owczarek, D. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i3.895 · Cited by 263
The microbiota-gut-brain axis and its potential therapeutic role in autism spectrum disorder
Li, Q., & Zhou, J.-M. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.03.013 · Cited by 253
“Abbreviations: 4EPS, 4-ethylphenylsulfate; 5-HT, 5-hydroxytryptamine; AA, acetic acid; ANS, autonomic nervous system; ASD, autism spectrum disorder; BBB, blood–brain barrier; CHD8, chromodomain helicase DNA-binding protein 8; CNS, central nervous system; CRH, corticotropin-releasing hormone; ENS, enteric nervous syste…”
Giannetti, E., Maglione, M., Alessandrella, A., Strisciuglio, C., De Giovanni, D., Campanozzi, A., Miele, E., & Staiano, A. (2017) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000528 · Cited by 102
Metadata
- Authors
- Guandalini, S.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2014-08-28
- Volume
- 1
- Pages
- 23-23
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W2028646226
- Cited by
- 44
- References
- 27
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.